Live Stock Coverage: What’s Next for AstraZeneca plc (ADR) After Today’s Significant Increase?

Live Stock Coverage: What's Next for AstraZeneca plc (ADR) After Today's Significant Increase?

The stock of AstraZeneca plc (ADR) (NYSE:AZN) is a huge mover today! About 7.81 million shares traded hands or 9.23% up from the average. AstraZeneca plc (ADR) (NYSE:AZN) has declined 12.39% since April 22, 2016 and is downtrending. It has underperformed by 17.80% the S&P500.
The move comes after 5 months positive chart setup for the $67.80B company. It was reported on Nov, 25 by Barchart.com. We have $27.86 PT which if reached, will make NYSE:AZN worth $2.03B more.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on February, 2. They expect $0.57 EPS, down 39.36% or $0.37 from last year’s $0.94 per share. AZN’s profit will be $1.43 billion for 11.86 P/E if the $0.57 EPS becomes a reality. After $1.32 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -56.82% negative EPS growth.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Swedbank given on Friday, July 31. The firm has “Hold” rating by Nordea given on Monday, November 2. The firm has “Buy” rating given on Friday, September 18 by Bryan Garnier & Cie. As per Tuesday, January 19, the company rating was upgraded by Barclays Capital. Deutsche Bank upgraded AstraZeneca plc (ADR) (NYSE:AZN) on Monday, September 14 to “Buy” rating. Leerink Swann maintained AstraZeneca plc (ADR) (NYSE:AZN) on Monday, May 2 with “Market Perform” rating. The firm has “Neutral” rating by BNP Paribas given on Wednesday, September 14. Jefferies downgraded the stock to “Hold” rating in Tuesday, March 15 report. The rating was initiated by Piperjaffray with “Overweight” on Friday, September 23. The rating was upgraded by Morgan Stanley to “Overweight” on Tuesday, December 1.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by Businessfinancenews.com which published an article titled: “AstraZeneca plc (ADR): What Are the Future Prospects?” on August 01, 2016.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment